Researcher’s Profile

Isaac George, MD

Surgical Director of the Heart Valve Center at Columbia
Director Hybrid Coronary Interventions, New York, NY
Ji R, Akashi H, Drosatos K, Liao X, Jiang H, Kennel PJ, Brunjes DL, Castillero E, Zhang X, Deng LY, Homma S, George I, Takayama H, Naka Y, Goldberg IJ, Schulze PC.  Increased de novo ceramid synthesis and accumulation of ceramides in failing myocardium.  (submitted)
Castano A, Narotsky D, Morgenstern R, Hamid N, Khalique OK, Rubin J, Chiuzan C, Nazif T, Vahl T, George I, Kodali S, Leon MB, Hahn RT, Bokhari S, Maurer MS.  Unveiling Transthyretin Cardiac Amyloidosis and its Predictors Among Patients with Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement.
Zhang X, Ji R, Liao X, Castillero E, Kennel PJ, Brunjes D, Drosatos K, George I, Chen E, Schulze PC.  miR-195 Regulates Myocardial Metabolism in Heart Failure via Alterations in SIRT3 Expression and Mitochondrial Proteins Acetylation Profile.  (submitted)
Langer NB, Hamid NB, Nazif TM, Khalique O, Vahl TP, White J, Terre J, Hastings R, Leung D, Hahn RT, Leon MB, Kodali SK, George I.  Injuries to the Aorta, Aortic Annulus, and Left Ventricle During Transcathether Aortic Valve Replacement: Management and Outcomes.  (submitted)
Salna M, Nazif T, Khalique OK, Vahl T, Chiuzan C, White J, Hamid N, Hastings R, Terre J, Patel A, Wang C, Wu Y, Park JE, Kurlansky P, Bapat V, Borger M, Hahn RT, Leon MB, Smith CR, Kodali SK, George I.  Comparative Impact of Small Prosthesis Size on Patients undergoing Transcatheter or Surgical Aortic Valve Replacement.  (submitted)

Dr. Isaac George, MD joined NewYork Presbyterian/Columbia University Medical Center in the Department of Surgery in July of 2001 as an resident in general surgery following his graduation from Duke University School of Medicine. Prior to receiving his MD, Dr. George completed a B.S. in Mechanical Engineering at Massachusetts Institute of Technology in 1997. Dr. George also completed a fellowship program in cardiothoracic surgery in 2011 as well as a fellowship program in interventional cardiology in 2012. In July, 2012 Dr. George became an Assistant Professor of Surgery.

Dr. George is board certified in thoracic surgery and general surgery. He performs all types of open complex adult cardiac surgery (aortic, mitral and tricuspid valve surgery, aortic aneurysm surgery, coronary bypass grafting, robotic surgery) and annually performs 200+ open heart surgeries a year. He is one of the few physicians in the world trained in both cardiac surgery and interventional cardiology, and is currently the Surgical Director of the Structural Heart and Valve Center at Columbia University Medical Center.

Dr. George is focused on integrating new technology and innovation into his clinical practice. He is trained in the most current and cutting-edge procedures including Transcatheter Aortic and Mitral Valve Replacement (TAVR, TMVR), transcatheter valvular repair, percutaneous coronary stenting, and aortic stent grafting. He performs over 500 transcatheter valve procedures a year, in addition to his busy open surgical practice and has personally done almost 2000 TAVR procedures. Because he is trained in multiple disciplines, he is able to combine strategies to create a personalized treatment for each individual patient. As Primary Investigator of a national TAVR trial and with involvement in numerous other clinical trials, he has extensive clinical research trial experience. 

Dr. George is involved in both benchtop and clinical research as well. His primary scientific goals involve the regulatory mechanisms of myostatin (a negative regulator of muscle growth) to insulin-like growth factor-1 and its role in cardiac hypertrophy and cardiomyopathy. Specifically, his group is the first to report the importance of myostatin activation in heart failure. As director of the cardiac surgery research laboratory, he oversees surgical fellows, post-doctoral students, masters students, and research assistants in both scientific projects and clinical outcomes in cardiac surgery and TAVR. His projects reflect the translational nature of the lab as well as his clinical interests. His clinical practice allows him to be uniquely positioned to advance this research with a clinical endpoint and potential therapeutic intervention as the goal.